Quesada AA, Bolaños CA

Language: Spanish
References: 39
Page: 83-90
PDF size: 256.00 Kb.

ABSTRACT

Hyperhomocysteinemia is associated with an increased risk of vascular disease in observational studies and in case-control studies. Elevations in Homocysteine (Hcy) induce pathological changes in the arterial wall, endothelium, oxidative stress, inflammation and clotting that leads to atherosclerosis, a common manifestation of cerebrovascular events, cardiovascular and peripheral vascular disease. Because of this, there have been many studies aimed at determining whether the decrease in plasma Hcy levels with folic acid or vitamin B complex may be useful to prevent coronary artery disease. Although, these studies showed an effective reduction of hyperhomocysteinemia, they couldn’t find a reduction in cardiovascular risk that calls into question whether hyperhomocysteinemia is a risk factor, a consequence or a marker of cardiovascular disease.

REFERENCES

1. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008; 299: 2027-36.

2. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008; 299: 2027-36.

3. Akalin A, Alatas O, Colak O. Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients. European Journal of Endocrinology 2008; 158: 47–52.

4. Arif S, Lutfullah G, Iftikhar B, et al. Homocysteine and Acute Myocardial Infarction. J. Med. Sci 2010 January; 18(1): 54-58.

5. Baby B, Saravanan G, Chinnaswamy P. Elevated concentrations of plasma homocysteine in coronary artery disease patients with normal folate level. J. Pharm. Sci. & Res.2009; 1(2): 51-56.

6. Bazzano LA, Reynolds K, Holder KN, He J. Effect of Folic Acid Supplementation on Risk of Cardiovascular Diseases. A Meta-analysis of Randomized Controlled Trials. JAMA. 2006 December; 296(22): 2720-2726.

7. Bønaa KH, Njølstad I, Ueland PM, et al; for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354

8. Cañizares R, Navarroa J, García P, et al. Factores de riesgo vascular. Medicine. 2009;10(40):2668-77

9. De Koning L, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clinical Biochemistry 2003; 36: 431–441.

10. Djuric D, Jakovljevic V, Rasic-Markovic A, Djuric A, Stanojlovic O. Homocysteine, Folic Acid and Coronary Artery Disease: Possible Impact on Prognosis and Therapy. Indian J Chest Dis Allied Sci 2008; 50: 39-48.

11. Ebbing M, Bleie O, Ueland PM, et al. Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography. A Randomized Controlled Trial. JAMA. 2008 August; 300(7): 795-804.

12. Farbstein D, Levy AP. The Genetics of Vascular Complications in Diabetes Mellitus. Cardiol Clin 2010; 28: 477–496.

13. Gader A, Abdulla SH, Kordofani AY. Plasma homocysteine levels in cardiovascular disease, malaria and protein–energy malnutrition in Sudan. Eastern Mediterranean Health Journal 2009; 15(6): 1432-1439.

14. Ghaedi M, Zeinali H, Boroumand MA, Abbasi SH. Homocysteine level in CAD patients of Iranian population. Iranian Cardiovascular Research Journal 2007; 1(2): 92-97.

15. Gravina-Taddei CF, Batlouni M, Sarteschi C, et al. Hyperhomocysteinemia as a Risk Factor for Coronary Atherosclerotic Diseases in the Elderly. Arquivos Brasileiros de Cardiologia 2005, September; 85(3): 1-8.

16. Guilliams T. Homocysteine – A Risk Factor for Vascular Diseases: Guidelines for the Clinical Practice. JANA 2004; 7(1): 10-24.

17. Guo H, Chi J, Xing Y, Wang P. Influence of folic acid on plasma homocysteine levels & arterial endothelial function in patients with unstable angina. Indian J Med Res 2009 March; 129: 279-284.

18. Harjai KJ. Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen. Ann Intern Med 1999 September; 131: 376-386.

19. HOPE-2 Heart Outcomes Prevention Evaluation Investigators. Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. N Engl J Med 2006 April; 354: 1567-77.

20. Huang T, Yuan G, Zhang Z, Zou Z, Li D. Cardiovascular pathogenesis in hyperhomocysteinemia. Asia Pac J Clin Nutr 2008; 17(1): 8-16.

21. Hussain A, Nawaz A, Mushtaque A, Fasih S, Saleh M. Hyperhomocysteinemia, a Risk Factor for Myocardial Infarction in Patients with Type-2 Diabetes in Southern Sindh, Pakistan. Pakistan Journal of Nutrition 2009; 8(11): 1753-1755.

22. Khurelbaatar MU, Erdenekhuu N, Altantsetseg P, Zulgerel D, Huang SL. Asymptomatic Mongolian middle-aged women with high homocysteine blood level and atherosclerotic disease. Heart Vessels 2010; 25: 7–13.

23. Karolczak K, Olas B. Mechanism of Action of Homocysteine and Its Thiolactone in Hemostasis System. Physio Res 2009; 58: 623-633.

24. Keles T, Durmaz T, Akar N, et al. The Relationship between Plasma Homocysteine and Early Coronary Collateral Vessel Development after Acute Myocardial Infarction. Turk J Med Sci 2009 April; 39(2): 167-172.

25. Khan S, Chauhan UK, Dwivedi MK, Tripathi AK, Shukla S. Cardiovascular Disease and Risk Factors. International Journal of Biotechnology and Biochemistry 2009; 6(3): 377–389.

26. Lentz SR, Haynes WG. Homocysteine: Is it a clinically important cardiovascular risk factor? Cleveland Clinic Journal of Medicine 2004 September; 71(9): 729-734.

27. Lentz SR. Mechanisms of homocysteineinduced atherothrombosis. Journal of Thrombosis and Haemostasis 2005; 3: 1646-1654.

28. Marinou K, Antoniades C, Tousoulis D, et al. Homocysteine: A Risk Factor for Coronary Artery Disease? Hellenic J Cardiol 2005; 46: 59-67.

29. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2009; 4: Art. No.: CD006612. http://www2.cochrane.org/reviews/en/ab006612.html.

30. Masoomi M, Bahrampour A, Mireskandri M, Nematolahi A. Plasma Homocysteine Concentrations in Young Patients with Acute Myocardial Infarction. ARYA Atherosclerosis Journal 2007, 2(4): 193-196.

31. Matetzky S, Freimark D, Ben-Ami S, et al. Association of Elevated Homocysteine Levels With a Higher Risk of Recurrent Coronary Events and Mortality in Patients With Acute Myocardial Infarction. Arch Intern Med. 2003 September; 163: 1933-1937.

32. McCully KS. Chemical Pathology of Homocysteine. IV. Excitotoxicity, Oxidative Stress, Endothelial Dysfunction, and Inflammation. Annals of Clinical & Laboratory Science 2009; 39(3): 307-320.

33. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.

34. Mujawar SA, Patil VW, Daver RG. Cortisol: Testosterone ratio and homocysteine levels in patients with acute myocardial infarction. Biomedical Research 2010; 21(2): 179-183.

35. Nusier MK, El-Dwairi QA. Effects of Vitamin B12 and Folic Acid on Hyperhomocysteinemia in Patients with Acute Myocardial Infarction. Journal of Health Science 2007; 53(1): 16-22.

36. SEARCH Study Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010 Jun 23;303(24):2486-94.

37. Selhub J. Homocysteine Metabolism. Annu. Rev. Nutr 1999; 19: 217–46.

38. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291(5): 565-575.

39. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, doubleblind, parallel, placebo-controlled trial. Lancet Neurol. 2010 September; 9(9):855-65.